News

Merck KGaA sells Allergopharma to Dermapharm

Read time: 1 mins

Published:20th Feb 2020

Merck KGaA, a leading science and technology company, signed an agreement to sell its allergy business Allergopharma to Dermapharm Holding SE . The transaction, which is expected to close by the end of the second quarter 2020, is subject to regulatory approval and satisfaction of other customary closing conditions.

Type: industry

Learning Zone Homepage

Advances in HS

The latest updates in HS from the 2024 European Hidradenitis Suppurativa Foundation Conference, 7–9 February in Lyon

Learning Zone

All Things Angioedema and Urticaria: Podcasts

In these podcasts, our hosts, Professor Marcus Maurer and Dr Thomas Buttgereit are joined by friends and colleagues to discuss all things related to angioedema and urticaria.

Learning Zone Homepage

Ulcerative colitis Learning Zone

Explore the role of biologics and targeted small molecules in UC management, and listen to expert insights on integrating them into practice.

Learning Zones

The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.

Click here to view

Related news and insights

Drug news

Tirzepatide reduced sleep apnea severity by up to nearly two-thirds in adults with obstructive sleep apnea (OSA) and obesity

Eli Lilly and Company announced positive topline results of the SURMOUNT-OSA phase III clinical trials that showed tirzepatide injection (10 mg or 15 mg) significantly reduced the apnea-hypopnea index (AHI) compared to placebo, achieving the primary endpoints

2 mins

Drug news

Topline results from phase II PRECEDENT study of dalzanemdor (SAGE 718) in the treatment of mild cognitive impairment in Parkinson’s disease

Sage Therapeutics, Inc. announced topline results from PRECEDENT, a double-blind, placebo-controlled Phase II study of the investigational oral medicine dalzanemdor (SAGE-718) in people with mild cognitive impairment (MCI) in Parkinson’s Disease (PD)

1 min

Drug news

Kesimpta (ofatumumab) six-year efficacy data show substantial benefits in recently diagnosed treatment- naïve people with relapsing multiple sclerosis

Novartis announced new long-term data from the ALITHIOS open-label extension study showing that up to five years, patients treated earlier and continuously with Kesimpta (ofatumumab) had fewer disability worsening events and low brain volume change versus those who started on teriflunomide and were later switched to Kesimpta

6 min

See all news